Last reviewed · How we verify
Allogeneic bone marrow transplantation
Approved treatments
- Busilvex · medac GmbH
- Busulfex · Waylis
Busulfex works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death. - busulfex · Dana-Farber Cancer Institute
- Busulphan · University of Birmingham
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Allogeneic bone marrow transplantation patent landscape — cliff calendar, originator estates, attackable patents
- Allogeneic bone marrow transplantation treatment landscape brief
- Allogeneic bone marrow transplantation treatment updates RSS
Frequently asked questions about Allogeneic bone marrow transplantation
What drugs treat Allogeneic bone marrow transplantation?
Tracked treatments include Busilvex, Busulfex, busulfex, Busulphan.
What is the treatment for Allogeneic bone marrow transplantation?
Standard treatment for Allogeneic bone marrow transplantation includes Busilvex, Busulfex, busulfex, Busulphan. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Allogeneic bone marrow transplantation patent cliff · Allogeneic bone marrow transplantation CI report
- Treatment: Busilvex · medac GmbH
- Treatment: Busulfex · Waylis
- Treatment: busulfex · Dana-Farber Cancer Institute
- Treatment: Busulphan · University of Birmingham
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing